CMO Selection Under Supply Chain Pressure
Evaluate manufacturing partnership decisions balancing cost, control, and supply chain resilience in biotech scaling
Your biotech startup has completed Phase 2 trials for a novel monoclonal antibody therapeutic. The FDA signaled conditional approval is likely in 18 months. You need to secure manufacturing capacity now, but your Series B funding is 40% lower than projected due to market conditions. Your lead CMO candidate in Singapore offers 30% cost savings and proven GMP expertise, but sources 60% of raw materials from a single supplier in India. A domestic CMO in Pennsylvania charges 40% premium but has dual-sourced critical inputs across three countries. A third option—partial in-house manufacturing with a smaller CMO partnership—requires $8M capex you…
Sign up free — one personalized lesson every day, matched to your role and goals.
Already have an account? Sign in